In January–June 2023, Russian manufacturers produced 342.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), down 2.6% from the same period in 2022. In physical terms, the production volume was 1.97 billion packages, down 8.2%, or 39.0 billion minimum dosage units (MDU), down 3.8%.

May and June had a major influence on the results of the first six months. In particular, the production volume of ready-made drugs in June 2023 increased by 15.5% (to 60.5 billion rubles), which is the best growth rate in 2023, as well as the best since September 2022. In physical terms, however, Russian manufacturers produced around 332 million packages, down 0.3% from June 2022.

The number of manufacturers in the first half of 2023 was 406, up 28 from January–June 2022. The number of INNs was 1,350, up 58, while the number of SKUs was 8,403, up 607.

The volume of prescription drugs manufactured in January–June 2023 fell 3.6% in physical terms from the same period in 2022. The number of prescription drug manufacturers was 339, up 32 from January–June 2022. MBA-Group had the best growth rates—its production went up 58 times against January–June 2022, on last year’s low base. In 2023, the company manufactured two pharmaceutical drugs, with Ritonavir, produced at PharmVILAR in Kaluga Oblast, contributing to the growth rates the most. Elius came second—its production volume increased 48 times against January–June 2022. The company produced two drugs as well, and the production of Nozefrin Alergy, localized at Vertex in St. Petersburg, contributed to the growth rates the most. Among the top 100 manufacturers, Endokrinnye Tekhnologii had the highest growth rates (8.3 times), manufacturing as many as eight various pharmaceuticals. The company’s Nefopam helped the growth rates the best.

As for OTC drugs, the production volume went down 12% in packages. The number of manufacturers was 177, up 9 from January–June 2022. Farmanova had the best growth rates; it manufactured three OTC drugs, with Naphthyzin contributing to the growth rates the most. Woerwag Pharma increased its production volume 8 times against January–June 2023, manufacturing only Magnerot at Pik-Farma in Belgorod Oblast.